comparemela.com

Latest Breaking News On - Controlled equity - Page 4 : comparemela.com

GUGGENHEIM STRATEGIC OPPORTUNITIES FUND : COMMON SHARES (PAR VALUE $0 01 PER SHARE) THIRD AMENDMENT TO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT - Form 8-K

GUGGENHEIM STRATEGIC OPPORTUNITIES FUND COMMON SHARES THIRD AMENDMENT TO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT . | April 11, 2023

United statesBriane binderGuggenheim strategic opportunities fundGuggenheim funds investment advisorsCantor fitzgerald coCf coDelaware the fundSales agreementCantor fitzgeraldControlled equityFirst amendmentCommon sharesSecond amendmentChief executive officerThird amendmentSage kelly

BioVie : Sales Agreement - Form 8-K | MarketScreener

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13. | April 7, 2023

United statesCarson citySherman howardJoanne wendy kimSecurities exchangeCompany classExchange commission onCantor fitzgerald coNasdaq stock marketB riley securities incBiovie incCommission file numberExact nameIts charterNye lanesuitePrincipal executive offices

ALTUS POWER, INC : Entry into a Material Definitive Agreement (form 8-K)

Item 1.01. Entry into a Material Definitive Agreement. On April 6, 2023, Altus Power, Inc, a Delaware corporation , entered into a Controlled Equity OfferingSM Sales Agreement . | April 6, 2023

United statesCompany classCantor fitzgerald coTruist securities incManagement of the companyYork stock exchangeNomura securities international incAltus power incExchange commissionMaterial definitiveControlled equitySecurities internationalSales agreementSecurities actCurrent reportAltus power

SCYNEXIS : 10-K Filing | MarketScreener

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K . | March 31, 2023

State of new jerseyNew jerseyUnited statesHong kongUnited kingdomNew south walesSouth africaRussian federationDavid hastingsBrian philippe tinmouthMarco tagliettiAzoles noxafilStevenc gilmanChristine coyneHistoplasmaandblastomycesgenera candidaandaspergillusgeneraArmando anido

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Zynerba

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan. | March 29, 2023

United statesLincoln parkJim fickenscherPeter vozzoArmando anidoEuropean medicines agencyAmerican college of neuropsychopharmacologySilicon valley bankExchange commissionDrug administrationZynerba pharmaceuticals incHc wainwright coEuropean commissionLadenburg thalmann coTrademark officeVp corporate development

vimarsana © 2020. All Rights Reserved.